Desmoteplase clinical trials
How each study uses Desmoteplase is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- Desmoteplase
- 6
Studies by the year they started
6 studies that test it; most in 2001 (1)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2003 | 1 |
| 2005 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
H. Lundbeck A/S (2) · PAION Deutschland GmbH (2) · Lundbeck Japan K. K. (1) · Forest Laboratories (1)
Related medicines
As reviewed, each with the page that says it.
- One of Thrombolytics source
Studies
Open first, then newest update. How each study uses Desmoteplase is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Clinical Study of Desmoteplase in Japanese Patients With Acute Ischemic StrokeCompletedPhase 2Lundbeck Japan K. K.NCT01104467Written as DesmoteplaseHow we know
- Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)TerminatedPhase 3H. Lundbeck A/SNCT00856661Written as DesmoteplaseHow we know
- Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic StrokeCompletedPhase 3H. Lundbeck A/SNCT00790920Written as DesmoteplaseHow we know
- Study of Desmoteplase (International Nonproprietary Name [INN]) in Acute Ischemic Stroke (DIAS-2)CompletedPhase 3Forest LaboratoriesNCT00111852Written as DesmoteplaseHow we know
- Dose Escalation of Desmoteplase in Acute Ischemic Stroke (DEDAS)CompletedPhase 1/2PAION Deutschland GmbHNCT00638248Written as DesmoteplaseHow we know
- Desmoteplase in Acute Ischemic Stroke (DIAS)CompletedPhase 2PAION Deutschland GmbHNCT00638781Written as DesmoteplaseHow we know
Codes
What other systems call Desmoteplase · ClinicalTrials.gg INT003575
- UNII (FDA) T36L245S3TDESMOTEPLASEConfirmed FDA, Wikidata
- Wikidata Q409748DesmoteplaseConfirmed FDA, Wikidata
- NCI Thesaurus C87246DesmoteplaseOne source FDA
- DrugBank DB04925One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | T36L245S3T | DESMOTEPLASE | Confirmed FDA, Wikidata |
| Wikidata | Q409748 | Desmoteplase | Confirmed FDA, Wikidata |
| NCI Thesaurus | C87246 | Desmoteplase | One source FDA |
| DrugBank | DB04925 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.